oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
Company profile
Ticker
ORIC
Exchange
Website
CEO
Jacob Chacko
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
471787157
ORIC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
12 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
6 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
29 Mar 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
Transcripts
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 50.32 mm | 50.32 mm | 50.32 mm | 50.32 mm | 50.32 mm | 50.32 mm |
| Cash burn (monthly) | 2.18 mm | 4.49 mm | 12.01 mm | 10.43 mm | 8.54 mm | 8.31 mm |
| Cash used (since last report) | 9.18 mm | 18.93 mm | 50.64 mm | 43.98 mm | 36.03 mm | 35.05 mm |
| Cash remaining | 41.14 mm | 31.39 mm | -318.11 k | 6.34 mm | 14.29 mm | 15.27 mm |
| Runway (months of cash) | 18.9 | 7.0 | -0.0 | 0.6 | 1.7 | 1.8 |
Institutional ownership, Q2 2024
| 13F holders | Current |
|---|---|
| Total holders | 118 |
| Opened positions | 91 |
| Closed positions | 4 |
| Increased positions | 12 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 469.06 bn |
| Total shares | 88.12 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| PFE Pfizer | 5.38 mm | $31.08 mm |
| Nextech Invest | 5.29 mm | $37.37 bn |
| FMR | 4.92 mm | $34.79 bn |
| BLK BlackRock | 4.83 mm | $34.15 bn |
| Venrock Healthcare Capital Partners III | 4.43 mm | $46.54 mm |
| VR Adviser | 4.39 mm | $31.07 bn |
| Nextech Crossover I GP S.a r.l. | 4.29 mm | $36.00 mm |
| Frazier Life Sciences Management | 4.14 mm | $29.29 bn |
| Viking Global Investors | 4.00 mm | $28.28 bn |
| Alkeon Capital Management | 3.80 mm | $26.89 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Jun 24 | Heyman Richard A. | Stock Option Common Stock | Grant | Acquire A | No | No | 7.9 | 25,600 | 202.24 k | 25,600 |
| 12 Jun 24 | Mardi Dier | Stock Option Common Stock | Grant | Acquire A | No | No | 7.9 | 25,600 | 202.24 k | 25,600 |
| 12 Jun 24 | Hoerter Steven L. | Stock Option Common Stock | Grant | Acquire A | No | No | 7.9 | 25,600 | 202.24 k | 25,600 |
| 12 Jun 24 | Lori Anne Kunkel | Stock Option Common Stock | Grant | Acquire A | No | No | 7.9 | 25,600 | 202.24 k | 25,600 |
| 12 Jun 24 | Angie You | Stock Option Common Stock | Grant | Acquire A | No | No | 7.9 | 25,600 | 202.24 k | 25,600 |
News
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
4 Nov 24
Wells Fargo Initiates Coverage On ORIC Pharmaceuticals with Overweight Rating, Announces Price Target of $20
31 Oct 24
Jones Trading Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $17
31 Oct 24
Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
23 Sep 24
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
18 Sep 24
Press releases
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
4 Nov 24
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Nov 24
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
23 Oct 24
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it's Board of Directors
16 Oct 24
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
9 Oct 24